Acute Intermittent Hypoxia for Spinal Cord Injury
Trial Summary
What is the purpose of this trial?
The goal of this study is to clarify mechanisms of acute intermittent hypoxia and to examine the effect on lower limb function in persons with chronic, incomplete spinal cord injury.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Acute Intermittent Hypoxia for Spinal Cord Injury?
Research shows that Acute Intermittent Hypoxia (AIH) can improve motor function in individuals with chronic spinal cord injury by enhancing spinal plasticity, which is the ability of the spinal cord to adapt and recover. Studies in animal models and humans have demonstrated that AIH can lead to sustained improvements in both respiratory and non-respiratory motor functions.12345
Is acute intermittent hypoxia generally safe for humans?
Research on acute intermittent hypoxia (AIH) in humans, particularly those with spinal cord injuries, suggests it is generally safe, though individual responses can vary. Studies have shown AIH can enhance motor function and breathing, but more research is needed to fully understand its safety and effectiveness.12678
How does the treatment Acute Intermittent Hypoxia differ from other treatments for spinal cord injury?
Acute Intermittent Hypoxia (AIH) is unique because it involves brief, repeated exposures to low oxygen levels, which can trigger neuroplasticity (the brain's ability to reorganize itself) and improve breathing function in people with spinal cord injuries. Unlike traditional exercise-based rehabilitation, AIH is a time-efficient and potentially more accessible approach to enhance physical function and respiratory capacity.167910
Eligibility Criteria
This trial is for people aged 18-75 with chronic, incomplete spinal cord injuries between C2 and L5 levels or non-traumatic disorders like MS. They must be medically stable, over a year post-injury, and able to take one step unaided or with devices. Excluded are those with recent concussions, metal head implants/pacemakers, needle aversion, pregnancy plans, severe illnesses/pain, cardiovascular issues, untreated musculoskeletal problems or mental health conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Baseline measurements including MRI, 6-Minute Walk Test, and 10-Meter Walk Test are conducted
Treatment
Participants undergo 4 consecutive days of acute intermittent hypoxia or normoxia exposure
Follow-up
Participants are monitored for changes in biomarkers and functional tests after treatment
Treatment Details
Interventions
- Acute Intermittent Hypoxia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Boulder
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
University of Colorado, Denver
Collaborator